Nextech Invest Ltd. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001595430

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Q3 2026 · 17 positions · Total reported value $2.22B · Top-10 concentration 97.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 27.8% · 3 new · 1 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Nextech Invest Ltd. disclosed 17 equity positions with a combined reported value of $2.22B. The filing implies a focused portfolio: its ten largest positions account for 97.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($1.56B), PBLS ($150.57M), RLAY ($122.32M). By sector, the heaviest allocations are Health Care 98.7%, Other 1.3%. Versus the prior quarter, allocation shifted toward Other (+1.3pp) and away from Health Care (-1.3pp).

Versus the prior quarter, Nextech Invest Ltd. opened 3 new positions, trimmed 1 and fully exited 1, a turnover rate of 27.8% of positions. The portfolio's overlap with the prior quarter was 78% of names.

The largest new positions opened in Q3 2026 were ATOS ($31.45M), GRTX ($29.66M), AVTX ($11.74M).

Of the 1 positions fully exited versus the prior quarter, the largest were ARVN ($17.12M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ATOS ATOSSA THERAPEUTICS INC · $31.45M
  • GRTX ELECTRA THERAPEUTICS INC · $29.66M
  • AVTX AVALO THERAPEUTICS INC · $11.74M

Fully Exited (vs previous quarter)

  • ARVN ARVINAS INC · prev qtr: $17.12M

Insider Transactions (Form 4)

Latest Nextech Invest Ltd. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Nextech Invest Ltd. files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 15 positions worth $2.11B in total. HoldingsHub carries 6 quarters of its filings (Q1 2025–Q2 2026).

Portfolio Structure

  • 15 positions · $2.11B reported value (Q2 2026)
  • Top 10 holdings = 98.0% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 67.6%
  • Average position size: $140.49M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 added, 1 reduced, 3 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintains a concentrated, high-conviction position in biotech/healthcare (100% sector exposure), with a bullish tilt toward clinical-stage drug developers (e.g., RVMD, PBLS). No macro diversification suggests a focused view on healthcare innovation. 2. Key moves: - Reduced: TYRA (-3.0% shares, -2.0% weight). - Added: ALMS (+28.5% shares, -3.2% weight). - New positions: ATOS (1.41% weight), GRTX (1.33% weight). 3. Portfolio structure: Highly active, concentrated (top-10 holdings = 95.4% of AUM), and sector-specific (healthcare only). High risk appetite via small-cap biotech bets (e.g., KYMR, ZYME). 4. Per-holding one-liner: - RVMD: Revolution Medicines (oncology drug developer). - PBLS: Parabilis Medicines (unverified, likely biotech). - RLAY: Relay Therapeutics (kinase inhibitor drugs). - ORIC: Oric Pharmaceuticals (hepatitis B treatments). - TYRA: Tyra Biosciences (unverified, likely oncology). - ALMS: Alumis (obesity/metabolic disease drugs). - ATOS: Atossa Therapeutics (breast cancer therapy). - KYMR: Kymera Therapeutics (unverified, likely rare diseases). - GRTX: Electra Therapeutics (unverified, likely immunology). - ZYME: Zymeworks (bispecific antibody therapies). 5. Style summary: Biotech-focused active manager with concentrated bets on clinical-stage drug developers, selectively reducing TYRA while adding ALMS and new names ATOS/GRTX.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:10

Sector Allocation

Health Care 98.7%
Other 1.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 7.60M $1.56B 70.16%
70.16%
Hold
2 4.66M $150.57M 6.77%
6.77%
Hold
3 6.78M $122.32M 5.50%
5.50%
Hold
4 7.16M $96.48M 4.34%
4.34%
Hold
5 3.45M $75.40M 3.39%
3.39%
Reduce
6 4.55M $33.63M 1.51%
1.51%
Add
7 1.84M $31.45M 1.41%
1.41%
New
8 278.90K $31.18M 1.40%
1.40%
Hold
9 2.64M $29.66M 1.33%
1.33%
New
10 1.11M $29.51M 1.33%
1.33%
Hold
11 1.69M $18.51M 0.83%
0.83%
Add
12 4.45M $12.10M 0.54%
0.54%
Hold
13 766.00K $11.74M 0.53%
0.53%
New
14 761.15K $9.08M 0.41%
0.41%
Hold
15 450.00K $5.18M 0.23%
0.23%
Hold
16 2.32M $4.65M 0.21%
0.21%
Hold
17 7.42M $2.23M 0.10%
0.10%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 22% of its Top-10 each quarter and backtests at F1 78% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (4 quarters)

Avg precision 78% · recall 78% · F1 78% · avg rank error 1.4 · Top-10 turnover 22%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q3 80% 80% 80% RVMD · ORIC · TYRA · TNGX · KYMR · ZYME · RLAY · SPRY · CRGX · ARVN RVMD · ORIC · TYRA · TNGX · RLAY · KYMR · ZYME · ARVN · ALMS · CNTX
2025-Q4 80% 80% 80% RVMD · ORIC · TYRA · TNGX · RLAY · KYMR · ZYME · ALMS · ARVN · CNTX RVMD · TYRA · TNGX · ORIC · RLAY · ZYME · ALMS · KYMR · ENGN · MRSN
2026-Q1 80% 80% 80% RVMD · TYRA · TNGX · ORIC · RLAY · ZYME · ALMS · KYMR · ENGN · MRSN RVMD · TYRA · TNGX · ORIC · ALMS · RLAY · ZYME · KYMR · CTMX · CNTX
2026-Q2 ★ 70% 70% 70% RVMD · TNGX · TYRA · ORIC · ALMS · RLAY · ZYME · KYMR · CTMX · CNTX RVMD · PBLS · RLAY · TYRA · ALMS · ORIC · KYMR · ZYME · GLUE · ARVN

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings2 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-17.65%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return-0.64%vs benchmark
Barra annualised vol73.8%Model estimate
Realised vol60.8%Annualised in window
Weighted beta1.02Raw exposure
Factor / specific risk31% / 69%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16Nextech Invest Ltd.QQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-17.65%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return-0.64%Portfolio − benchmark
Arithmetic return sum-16.99%Difference vs compounded is the cross term
Weighted raw beta1.02Weighted holding betas
Realised volatility (annualised)60.77%Daily returns in window
Barra model volatility (annualised)73.77%Factor + specific
Factor share of variance30.7%Barra factors
Specific share of variance69.3%Stock residuals
Reported value$1.68B13F long US equity

2. Return attribution

The -16.99% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +4.35% 25.6%
Momentum & Growth 3 -16.18% -95.2%
Volatility & Tail Risk 7 +6.21% 36.5%
Industry 12 +6.98% 41.1%
Specific 1 -18.36% -108.0%
Return attribution (style + industry, %)-16.7-8.4+0.0+8.4+16.7Non-linear Size+0.27Skewness-0.55Beta+0.72Max Drawdown-0.80Short-term Reversal+1.11Mid Cap+1.16Historical Volatility+1.27Size+1.38Turnover+1.57Growth-1.80Kurtosis-3.60Health Care+6.98Residual Volatility+8.95Momentum-15.50
Factor Type Exposure Factor return Contribution Share of |return|
Residual Volatility Style +2.72 +3.29% +8.95% 52.7%
Health Care Industry +1.00 +6.98% +6.98% 41.1%
Turnover Style -0.33 -4.80% +1.57% 9.2%
Size Style -0.71 -1.95% +1.38% 8.1%
Historical Volatility Style -0.09 -14.00% +1.27% 7.5%
Mid Cap Style -0.60 -1.94% +1.16% 6.8%
Short-term Reversal Style +1.27 +0.87% +1.11% 6.5%
Beta Style +0.16 +4.44% +0.72% 4.2%
Non-linear Size Style +0.27 +1.01% +0.27% 1.6%
Leverage (Downside Vol) Style -0.13 -1.71% +0.22% 1.3%
Liquidity Style +0.22 +0.36% +0.08% 0.5%
Amihud Illiquidity Style +0.27 -0.45% -0.12% -0.7%
Skewness Style +0.12 -4.39% -0.55% -3.2%
Max Drawdown Style +0.45 -1.76% -0.80% -4.7%
Growth Style -1.03 +1.75% -1.80% -10.6%
Kurtosis Style -0.48 +7.51% -3.60% -21.2%
Momentum Style +3.87 -4.00% -15.50% -91.2%
Specific Specific — — -18.36% -108.0%

3. Risk attribution

Annualised volatility is 73.77%; factor risk explains 30.7% of variance and specific risk 69.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-74.9-37.4+0.0+37.4+74.9Growth-2.34Kurtosis-0.47Non-linear Size-0.28Liquidity+0.23Size+0.56Max Drawdown+0.58Beta+0.71Short-term Reversal+3.05Health Care+5.07Residual Volatility+5.56Momentum+17.67Specific+69.32
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 69.3% +51.14% 51.1%
Momentum Style +3.87 17.7% +13.03% 13.0%
Residual Volatility Style +2.72 5.6% +4.10% 4.1%
Health Care Industry +1.00 5.1% +3.74% 3.7%
Short-term Reversal Style +1.27 3.0% +2.25% 2.2%
Beta Style +0.16 0.7% +0.52% 0.5%
Max Drawdown Style +0.45 0.6% +0.43% 0.4%
Size Style -0.71 0.6% +0.42% 0.4%
Liquidity Style +0.22 0.2% +0.17% 0.2%
Non-linear Size Style +0.27 -0.3% -0.21% -0.2%
Kurtosis Style -0.48 -0.5% -0.35% -0.3%
Growth Style -1.03 -2.3% -1.72% -1.7%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.5-0.01.42.94.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.71 +2.10 -2.81
Non-linear Size +0.27 +1.68 -1.41
Mid Cap -0.60 +0.13 -0.73
Beta +0.16 +1.29 -1.13
Momentum +3.88 +0.72 +3.16
Short-term Reversal +1.27 -0.64 +1.91
Residual Volatility +2.72 -0.40 +3.12
Historical Volatility -0.09 +0.86 -0.95
Liquidity +0.22 +0.11 +0.11
Amihud Illiquidity +0.27 +1.16 -0.89
Turnover -0.33 +0.21 -0.53
Growth -1.03 +0.58 -1.61
Leverage (Downside Vol) -0.13 +0.14 -0.27
Skewness +0.12 +0.24 -0.11
Kurtosis -0.48 +0.21 -0.69
Max Drawdown +0.45 -0.08 +0.54

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -17.66% +8.29% +24.98% -0.45% -25.50% -17.80%
Total +23.98% +15.39% -41.34% -1.96%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
RVMD REVOLUTION MEDICINES INC Health Care 92.73% -18.70% -17.34% Hold
RLAY RELAY THERAPEUTICS INC Health Care 7.27% -4.32% -0.31% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 RLAY Health Care 7.27% -4.32% -0.31%
2 RVMD Health Care 92.73% -18.70% -17.34%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -17.65%, versus -17.01% for the QQQ synthetic benchmark — an excess of -0.64%.
  2. Return attribution: the largest positive style/industry contributions came from Residual Volatility +8.95%, Health Care +6.98%, Turnover +1.57%; the largest drags came from Momentum -15.50%, Kurtosis -3.60%, Growth -1.80%. Specific (stock-level) return contributed -18.36%.
  3. Risk attribution: Barra model volatility is 73.77% annualised; factor risk explains 31% of variance and specific risk 69%. The largest factor risk sources are Momentum 17.7%, Residual Volatility 5.6%, Health Care 5.1%.
  4. Style tilt: size -0.71, momentum +3.88, volatility -0.09, liquidity +0.22; the weighted raw beta is 1.02. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.39% and interaction -41.34%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Nextech Invest Ltd. buy in 2026-Q3?

In its 2026-Q3 13F filing, Nextech Invest Ltd. reported 17 equity positions worth $2.22B in aggregate; its largest disclosed positions were RVMD ($1.56B), PBLS ($150.57M), RLAY ($122.32M).

How large is Nextech Invest Ltd.'s portfolio?

Nextech Invest Ltd. reported $2.22B of long equity holdings across 17 positions as of 2026-Q3. Top-10 holdings account for 97.1% of reported value.

What is Nextech Invest Ltd.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/nextech-invest/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →